Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 17 | ||||||||||
answering dept short name | Health and Social Care | ||||||||||
answering dept sort name | Health and Social Care | ||||||||||
ddp modified |
|
||||||||||
hansard heading | Voluntary Scheme for Branded Medicines Pricing and Access | ||||||||||
house id | 2 | ||||||||||
identifier | HL6287 | ||||||||||
legislature |
|
||||||||||
parliament number | 58 | ||||||||||
question first answered |
|
||||||||||
question text | To ask His Majesty's Government what assessment they have made of the findings of the report by The Association of the British Pharmaceutical Industry False economy? How NHS medicine procurement threatens the UK’s Life Sciences growth engine, published on 23 February, that the continued current high rebate rates under the voluntary and statutory schemes for branded medicines during the next five years would mean foregoing £50 billion in GDP and £17.9 billion in tax revenues as a result of lost research and development investment; and what are their estimates of the value of the potential lost investment in this sector. | ||||||||||
session |
|
||||||||||
session number | 3 | ||||||||||
tabling member printed |
|
||||||||||
title | House of Lords Tabled Parliamentary Question 2022/23 HL6287 | ||||||||||
type |
|
||||||||||
uin | HL6287 | ||||||||||
version | 2 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher | 25277 | ||||||||||
tabling member |
|